Selenium sulfide for dandruff
FDA turns down Ross Laboratories' request that micronized selenium sulfide at 0.6% concentration be included in the final monograph for dandruff and seborrheic dermatitis as a Category I ingredient for dandruff control. FDA said only two out of five studies submitted by Ross "could be regarded as well-controlled clinical trials" and that only one study showed the ingredient more effective than shampoo base. "At least one additional well-controlled study of adequate sample size" is needed to support the efficacy of 0.6% micronized selenium sulfide, FDA stated.
You may also be interested in...
Dr Reddy’s signals a sharp step up in ambitions at home, propelled by building leadership in 10 therapy segments and an “India-first” approach for specialty products. Uptick in the China business and the potential launch of a Russia-partnered COVID-19 vaccine were other aspects of the business discussed at JPM.
“You can’t just live off the brand equity anymore,” warned J&J's Consumer Health's Minoj Raghunandanan during the ‘Advancing Trust in the Self-Care Industry’ webinar co-hosted by the Global Self-Care Federation and HBW Insight. “You’ve got to continue to build that trust between consumers and products day-in day-out.”
After almost a year as CEO of Centrient, Rex Clements reflects on the company’s experiences operating amid a pandemic that has underlined the importance of a diversified supply chain, while also highlighting the firm’s sustainable manufacturing initiatives and calling for non-price criteria to be taken into account by procurement processes, in an exclusive interview with Generics Bulletin.